SynoJoynt®

1% Sodium Hyaluronate



Arthrex®

SynoJoynt® 1% Sodium Hyaluronate

SynoJoynt 1% sodium hyaluronate is a high–molecular-weight, non-crosslinked sodium hyaluronate derived from bacterial fermentation. SynoJoynt HA is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics such as acetaminophen.

Excellent Safety and Tolerability[1]

- In a 6 month clinical trial, SynoJoynt 1% sodium hyaluronate demonstrated a safety profile similar to saline and Euflexxa® 1% sodium hyaluronate (Ferring Pharmaceuticals)
- Proven safety and efficacy in a 3-dose regimen
- No pseudoseptic reactions were reported for SynoJoynt HA during the clinical study
- The incidence of arthralgia, the most commonly reported side effect, was similar to saline

Key Attributes

- Non-avian source
- Not crosslinked
- Stable molecular weight of 2.5 million da
- Unique J code: J7331



Proven Relief[1]

The safety and effectiveness of SynoJoynt® 1% sodium hyaluronate was evaluated in a double-blind, prospective, multisite, randomized, three-arm, parallel group, pivotal trial in adults.[1] The primary objective of the study was to evaluate the effectiveness of 3 weekly intra-articular 2 mL doses of SynoJoynt HA, as compared to a placebo, injected into the target knee of subjects with knee OA.

Primary effectiveness endpoint was the change in baseline in the WOMAC arthritis pain score in the target knee at 26 weeks. Secondary effectiveness endpoints were the mean changes from baseline in the WOMAC pain, stiffness, and physical function scores over time. In total, 595 patients were treated and 543 completed the study. Demographics of participants were similar across study groups.

- From week 6 through week 26, SynoJoynt 1% sodium hyaluronate demonstrated statistically significant decreases in WOMAC pain scores, demonstrating superiority to the placebo
- At the 26-week timepoint, the mean changes in pain scores, stiffness, and physical function were significantly greater for SynoJoynt 1% sodium hyaluronate compared to the placebo
- Over time, the mean change in physical function was similar to Euflexxa 1% sodium hyaluronate



Osteoarthritic joints exhibit inflammation and degeneration



SynoJoynt HA provides proven lubrication and pain relief for mild to moderate OA

Least Squares Mean Change From Baseline in WOMAC Pain Score – Intent-to-Treat (ITT) Population



Ordering Information

Product Description	Item Number
SynoJoynt® 1% Sodium Hyaluronate	82197-0721-**16**

To order, please call Arthrex Customer Service at (800) 934-4404 or email your order to cstissue@arthrex.com. Products advertised in this brochure / surgical technique guide may not be available in all countries. For information on availability, please contact Arthrex Customer Service or your local Arthrex representative.

Indications for Use

SynoJoynt 1% sodium hyaluronate is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients that have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics (eg, acetaminophen).

Contraindications, Warnings, and Precautions

- SynoJoynt 1% sodium hyaluronate is contraindicated in patients with known hypersensitivity (allergy) to hyaluronate preparations or gram-positive bacterial proteins.
- Do not administer SynoJoynt 1% sodium hyaluronate to patients with infections or skin diseases in the area of the injection site or joint.
- The safety and effectiveness of the use of SynoJoynt 1% sodium hyaluronate has not been tested in pregnant women, nursing mothers or children.
- The safety and effectiveness of the use of SynoJoynt 1% sodium hyaluronate in joints other than the knee, or for use concomitantly with other intra-articular (IA) injections, have not been established.
- See package insert for full prescribing information including indications, contraindications, warnings, precautions, and adverse events.

Reference

1. US Food and Drug Administration. Summary of Safety and Effectiveness Data for SynoJoynt. Accessed June 26, 2023. https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170016B.pdf.

Arthrex®

arthrex.com